Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V(1A) and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

European Journal of Pharmacology

Volumn 376, Issue 3, 1999, Pages 239-246

  Yatsu, Takeyuki ^a   Tomura, Yuichi ^a   Tahara, Atsuo ^a   Wada, Koh ichi ^a   Kusayama, Toshiyuki ^a   Tsukada, Junko ^a   Tokioka, Tomoko ^a   Uchida, Wataru ^a   Inagaki, Osamu ^a   Iizumi, Yuichi ^a   Tanaka, Akihiro ^a   Honda, Kazuo ^a  

^a Inst Drug D   (Japan)

Author keywords

Congestive heart failure; Conivaptan hydrochloride; Vasoconstriction; Vasopressin receptor antagonist, non peptide; Water retention

Indexed keywords

CONIVAPTAN; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; PENTOBARBITAL; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIURESIS; DOG; DRUG EFFECT; FEMALE; HEART FUNCTION; HEART PACING; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; URINE OSMOLALITY; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOPRESSIN BLOOD LEVEL;

ANIMALS; BENZAZEPINES; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; DIURESIS; DOGS; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; RECEPTORS, VASOPRESSIN; RENAL AGENTS;

EID: 0032988191     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00379-9     Document Type: Article

References (41)

1. Armstrong P.W., Terrance P.S., Ford S.E., DeBold A.J. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 74:1986;1075-1084.
2. Arnolda L., McGrath B., Cocks M., Johnston C.I. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J. Clin. Invest. 78:1986;674-679.
3. Arnolda L., McGrath B., Johnston C.I. Systemic and regional effect of vasopressin and angiotensin in acute left ventricular failure. Am. J. Physiol. 260:1991;H499-H506.
4. Brands M.W., Alonso-Galicia M., Mizelle H.L., Montani J.P., Hildebrandt D.A., Hall J.E. Chronic angiotensin-converting-enzyme inhibition improves cardiac output and fluid balance during heart failure. Am. J. Physiol. 264:1993;R414-R422.
5. Cohn J.N. Current therapy of the failing heart. Circulation. 78:1988;1099-1107.
6. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patient with chronic congestive heart failure. N. Engl. J. Med. 311:1984;819-823.
7. Creager M.A., Faxon D.P., Cutler S.S., Kohlmann O., Ryan T.J., Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with renin-angiotensin system and the sympathetic nervous system. J. Am. Coll. Cardiol. 7:1986;758-765.
8. Dzau V.J., Hollenberg N.K. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann. Intern. Med. 100:1984;777-781.
9. Francis G.S. Neuroendocrine manifestations of congestive heart failure. Am. J. Cardiol. 62:1988;9A-13A.
10. Fujisawa G., Ishikawa S., Okada K., Sakuma N., Tsuboi Y., Saito T. Improvement by a nonpeptide vasopressin antagonist OPC-31260 of water retention in experimental rats with myocardial infarction. J. Am. Soc. Nephrol. 4:1993;852. Abstract.
11. Goldsmith S.R., Francis G.S., Cowley A.W. Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am. J. Cardiol. 58:1986;295-299.
12. Himura Y., Liang C.-S., Imai N., Delehanty J.M., Woolf P.D., Hood W.B. Short-term effects of naloxone on hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure. J. Am. Coll. Cardiol. 23:1994;194-200.
13. Ishikawa S., Saito T., Okada K., Tsutsui K., Kuzuya T. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. Kidney Int. 30:1986;49-55.
14. Kim J.K., Michel J.B., Soubrier F., Durr J., Corvol P., Schrier R.W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int. 38:1990;818-822.
15. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patient with severe chronic heart failure. Circulation. 73:1986;257-267.
16. Martin P.-Y., Schrier R.W. Sodium and water retention in heart failure: pathogenesis and treatment. Kidney Int. 51:1997;S57-S61. Suppl. 59.
17. Moe G.W., Stopps T.P., Angus C., Forster C., DeBold A.J., Armstrong P.W. Alternations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J. Am. Coll. Cardiol. 13:1989;173-179.
18. Mulinari R.A., Gavras I., Wang Y.-X., Franco R., Gavras H. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation. 81:1990;308-311.
19. Naitoh M., Suzuki H., Murakami M., Matsumoto A., Arakawa K., Ichihara A., Nakamoto H., Oka K., Yamamura Y., Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. 267:1994;H2245-H2254.
20. Nicod P., Waeber B., Bussien J.P., Goy J.J., Turini G., Nussberger J., Hofbauer K.G., Brunner H.R. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. 55:1985;1043-1047.
21. Nicod P., Biollaz J., Waeber B., Goy J.J., Polikar R., Schlapfer J., Schaller M.D., Turini G.A., Nussberger J., Hofbauer K.G., Brunner H.R. Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatremia. Br. Heart J. 56:1986;433-439.
22. Packer M. Therapeutic options in the management of chronic heart failure: is there a drug of first choice? Circulation. 79:1989;198-204.
23. Packer M. Pathophysiology of chronic heart failure. Lancet. 340:1992;88-92.
24. Packer M. Treatment of chronic heart failure. Lancet. 340:1992;92-95.
25. Parmley W.W. Pathophysiology and current therapy of congestive heart failure. J. Am. Coll. Cardiol. 13:1989;771-785.
26. Phillips, P.A., Burrel, L.M., Gow, C.B., Johnston, C.I., Grant, S., Risvanis, J., Aldred, K., 1995. Vasopressin antagonism: physiological and pharmacological roles. In: Saito, T., Kurokawa, K., Yoshida, S. (Eds.), Neurohypophysis Recent Progress of Vasopressin and Oxytocin Research. Elsevier, Amsterdam, pp. 643-658.
27. Raya T.E., Gay R.G., Goldman S. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilation. J. Pharmacol. Exp. Ther. 255:1990;1015-1020.
28. Riegger A.J., Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin. Sci. 62:1982;465-469.
29. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N. Engl. J. Med. 319:1988;1065-1072.
30. Spinale F.G., Zellner J.L., Tomita M., Crawford F.A., Zile M.R. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ. Res. 69:1991;1058-1067.
31. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305:1981;263-266.
32. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. 30:1997;759-766.
33. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282:1997;301-308.
34. 2 receptor antagonist. Naunyn-Shmiedeberg's Arch. Pharmacol. 357:1998;63-69.
35. Tahara A., Saito M., Sugimoto T., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 125:1998;1463-1470.
36. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. 38:1998;198-205.
37. Teranuma S., Yamakado T., Maeda M., Nakano T. Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog. Circulation. 95:1997;732-739.
38. Wang Y., Franco R., Gavras I., Gavras H. Effect of chronic administration of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. J. Lab. Clin. Med. 117:1991;313-318.
39. Xu D.-L., Martin P.-Y., Ohara M., John J.S., Pattison T., Meng X., Morris K., Kim J.K., Schrier R.W. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Invest. 99:1997;1500-1505.
40. 2 receptor antagonist, in dogs. Eur. J. Pharmacol. 321:1997;225-230.
41. 1 receptor agonist, in a canine model of acute congestive heart failure. Gen. Pharmacol. 30:1998;733-737.